Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

By LabMedica International staff writers
Posted on 23 Apr 2024

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. More...

Typically, patients initially respond to surgery and chemotherapy, but the cancer often returns. Now, researchers have used spatial analysis of tissue samples to uncover patterns that could indicate whether patients with this form of ovarian cancer are likely to experience early recurrence following treatment, potentially guiding future therapeutic strategies.

Researchers at Cedars-Sinai (Los Angeles, CA, USA) conducted spatial protein analyses on ovarian cancer tissue samples to identify patterns correlated with early cancer relapse soon after treatment. The study involved 42 patients and examined both primary and recurrent tumors using imaging mass cytometry, which allows for the detailed spatial examination of protein presence within tissues. Their key findings highlighted the role of plasma cells in the tumor's immune response.

The study found that the location of plasma cells and their relationship with nearby cell types, such as cancer-associated fibroblasts, were crucial indicators of patient outcomes. These fibroblasts, which hamper the effectiveness of immune cells, were frequently found in areas with plasma cells, suggesting that they may affect the plasma cells' ability to communicate with other immune cells, thus contributing to poorer outcomes in patients.

“Using spatial protein analysis, we looked not only at the types of cells within and around a tumor, but also at their relative positions and how they interact,” said Alex Xu, PhD, a research scientist at Cedars-Sinai Cancer. “Our findings suggest that plasma cells are a clinically important factor determining a patient’s time to relapse.”

Related Links:
Cedars-Sinai


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Pan-Cancer Panel
TruSight Oncology 500
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.